Markets:

Overview

News

Currencies

International

Treasuries

ADC Therapeutics SA Common Shares (NY:ADCT)

0.9804 +0.0203 (+2.11%)

Streaming Delayed Price Updated: 9:56 AM EDT, Aug 21, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about ADC Therapeutics SA Common Shares

< Previous 1 2 3 4 5 6 7 8 9 Next >

ADC Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Updates

August 08, 2023

From ADC Therapeutics SA

Via GlobeNewswire

A Preview Of ADC Therapeutics's Earnings ↗

August 07, 2023

Via Benzinga

ADC Therapeutics to Host Second Quarter 2023 Financial Results Conference Call on August 8, 2023

August 01, 2023

From ADC Therapeutics SA

Via GlobeNewswire

Stocks That Hit 52-Week Lows On Tuesday ↗

July 25, 2023

On Tuesday, 56 companies set new 52-week lows.

Via Benzinga

4 Analysts Have This to Say About ADC Therapeutics ↗

July 25, 2023

Via Benzinga

Stocks That Hit 52-Week Lows On Monday ↗

July 24, 2023

On Monday morning, 70 companies achieved new lows for the year.

Via Benzinga

Overland ADCT BioPharma Announces NMPA Accepts Biologics License Application and Grants Priority Review for ZYNLONTA® for Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma

July 24, 2023

From ADC Therapeutics SA

Via GlobeNewswire

Earnings Preview: ADC Therapeutics ↗

February 27, 2023

Via Benzinga

Stocks That Hit 52-Week Lows On Friday ↗

July 21, 2023

On Friday, 54 companies hit new 52-week lows.

Via Benzinga

ADC Therapeutics Pulls Plug On Mid-Stage Zynlonta Study In Untreated Lymphoma Patients After Patient Deaths ↗

July 21, 2023

ADC Therapeutics SA (NASDAQ: ADCT) announced that it plans to discontinue the Phase 2 LOTIS-9 trial evaluating Zynlonta (loncastuximab tesirine-lpyl) and rituximab in unfit or frail patients with...

Via Benzinga

ADC Therapeutics Announces Plan to Discontinue the Phase 2 LOTIS-9 Clinical Trial of ZYNLONTA® (loncastuximab tesirine-lpyl) and Rituximab in Unfit or Frail Previously Untreated DLBCL Patients

July 20, 2023

From ADC Therapeutics SA

Via GlobeNewswire

Dow Rises More Than 200 Points; Adial Pharmaceuticals Shares Spike Higher ↗

July 11, 2023

U.S. stocks traded higher toward the end of trading, with the Dow Jones surging more than 200 points on Tuesday. The Dow traded up 0.73% to 34,193.60 while the NASDAQ rose 0.25% to 13,720.16. The S&P...

Via Benzinga

Why Siyata Mobile Shares Are Trading Lower By 21%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

July 11, 2023

Gainers CytoMed Therapeutics Limited (NASDAQ: GDTC) shares climbed 129.5% to $8.01 after gaining 9% on Monday.

Via Benzinga

Crude Oil Rises 2%; ADC Therapeutics Shares Plummet ↗

July 11, 2023

U.S. stocks traded higher midway through trading, with the Dow Jones surging over 100 points on Tuesday. The Dow traded up 0.41% to 34,082.47 while the NASDAQ rose 0.29% to 13,725.52. The S&P 500, also...

Via Benzinga

Dow Jumps Over 100 Points; US Small Business Optimism Index Tops Estimates ↗

July 11, 2023

U.S. stocks traded higher this morning, with the Dow Jones gaining over 100 points on Tuesday. Following the market opening Tuesday, the Dow traded up 0.40% to 34,080.13 while the NASDAQ rose 0.23% to...

Via Benzinga

ADC Therapeutics Stock Is Plunging Today - What's Going On? ↗

July 11, 2023

ADC Therapeutics SA (NASDAQ: ADCT) has voluntarily paused enrollment of new patients in the Phase 2 LOTIS-9 trial evaluating Zynlonta (loncastuximab tesirine-lpyl) and rituximab (Lonca-R) in unfit or...

Via Benzinga

ADC Therapeutics Announces Voluntary Pause of Enrollment in the Phase 2 LOTIS-9 Clinical Trial of ZYNLONTA® (loncastuximab tesirine-lpyl) and Rituximab in Unfit or Frail Previously Untreated DLBCL Patients

July 11, 2023

From ADC Therapeutics SA

Via GlobeNewswire

ADC Therapeutics Announces Updated LOTIS-2 Results Demonstrating Durable, Long-Term Responses of ZYNLONTA® in Relapsed/Refractory DLBCL

June 09, 2023

Data being presented at the EHA 2023 Hybrid Congress will also be highlighted in an encore oral presentation at 17-ICML

From ADC Therapeutics SA

Via GlobeNewswire

ADC Therapeutics to Participate in the Jefferies Healthcare Conference

June 01, 2023

From ADC Therapeutics SA

Via GlobeNewswire

ADC Therapeutics Announces Updated Results from LOTIS-2 Trial to be Presented at the European Hematology Association 2023 Hybrid Congress

May 11, 2023

From ADC Therapeutics SA

Via Business Wire

ADC Therapeutics to Participate in the RBC Capital Markets Global Healthcare Conference

May 10, 2023

From ADC Therapeutics SA

Via Business Wire

ADC Therapeutics Reports First Quarter 2023 Financial Results and Provides Business and Strategy Update

May 09, 2023

From ADC Therapeutics SA

Via Business Wire

ADC Therapeutics to Host First Quarter 2023 Financial Results Conference Call on May 9, 2023

May 02, 2023

From ADC Therapeutics SA

Via Business Wire

Benzinga's Top Ratings Upgrades, Downgrades For April 24, 2023 ↗

April 24, 2023

Via Benzinga

ADC Therapeutics Releases its Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2022

March 15, 2023

From ADC Therapeutics SA

Via Business Wire

Stocks That Hit 52-Week Lows On Tuesday ↗

March 21, 2023

On Tuesday, 74 companies achieved new lows for the year.

Via Benzinga

ADC Therapeutics to Participate in the Cowen 43rd Annual Health Care Conference

March 01, 2023

From ADC Therapeutics SA

Via Business Wire

Stocks That Hit 52-Week Lows On Tuesday ↗

March 14, 2023

Tuesday's morning session saw 84 companies set new 52-week lows.

Via Benzinga

ADC Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates

February 28, 2023

From ADC Therapeutics SA

Via Business Wire

ADC Therapeutics to Host Fourth Quarter and Year-End 2022 Financial Results Conference Call on February 28, 2023

February 21, 2023

From ADC Therapeutics SA

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.